Date: 2016-01-18
Type of information: Nomination
Compound:
Company: Silence Therapeutics (UK)
Therapeutic area:
Type agreement: nomination resignation
Action mechanism:
Disease:
Details: * On January 18, 2016, Silence Therapeutics announced the appointment of Stuart Collinson D.Phil MBA, as Non-Executive Director of the Company, with immediate effect. Silence also announces the resignation of Simon Sturge as Non-Executive Director of the Company, with immediate effect. Simon has decided to resign from the Board due to his other business commitments. Stuart will take on the role of Chair the Remuneration Committee.
Dr. Collinson has held executive and senior management positions in public and private life science companies in the US and Europe. He is a partner of Forward Ventures, a biopharmaceutical venture capital fund, Chairman and CEO of Tioga Pharmaceuticals and Director of Arcturus Therapeutics and Essentialis. Stuart was Chairman, Chief Executive Officer and President of previously listed Aurora Biosciences (acquired by Vertex Pharmaceuticals) and subsequently Director of Vertex Pharmaceuticals Inc. (2001-2011). Stuart was also previously a director of several biopharmaceutical companies including Affinium Pharmaceuticals (acquired by Debiopharma Group), Asteres, CabrellisPharmaceuticals(acquired by Pharmion , now part of Celgene),Conforma Therapeutics (acquired by BiogenIdec), GeneOhm Sciences, (acquired by Becton, Dickinson and Company), NovaCardia (acquired by
Merck & Co), Oxagen and Sequel Pharmaceuticals. Stuart was awarded an MBA from Harvard Business School and a D.Phil in Physical Chemistry from the University of Oxford.
Financial terms:
Latest news:
